Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Stanex Drugs & Chemicals is an Indian private pharmaceutical manufacturer focused on generic specialty injectables, including non-beta-lactam and beta-lactam sterile products, along with APIs, veterinary formulations, nutraceuticals, and contrast media. The company states that it began operations in veterinary products in 1995 and expanded into human injectables in 2004 with a manufacturing facility in Hyderabad, Telangana. Stanex markets and manufactures products in therapeutic areas such as cardiology, nephrology, anti-infectives, and gastrointestinal care, and also offers third-party manufacturing, contract development, regulatory support, and out-licensing for semi-regulated markets. Its product portfolio includes molecules such as streptokinase, heparin sodium, iron sucrose, caspofungin, tigecycline, vancomycin, ertapenem, omeprazole, pantoprazole, and gadolinium-based contrast agents. The business appears to be a commercial-stage generic pharma manufacturer rather than a clinical-stage biotech company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stanex Drugs & Chemicals.